• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report.
【24h】

Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report.

机译：慢性自发性荨麻疹的临床需求未得到满足。 GA（2）LEN工作队报告。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chronic spontaneous urticaria, formerly also known as chronic idiopathic urticaria and chronic urticaria (CU), is more common than previously thought. At any time, 0.5-1% of the population suffers from the disease (point prevalence). Although all age groups can be affected, the peak incidence is seen between 20 and 40 years of age. The duration of the disease is generally 1-5 years but is likely to be longer in more severe cases, cases with concurrent angioedema, in combination with physical urticaria or with a positive autologous serum skin test (autoreactivity). Chronic spontaneous urticaria has major detrimental effects on quality of life, with sleep deprivation and psychiatric comorbidity being frequent. It also has a large impact on society in terms of direct and indirect health care costs as well as reduced performance at work and in private life. In the majority of patients, an underlying cause cannot be identified making a causal and/or curative treatment difficult. Nonsedating H-antihistamines are the mainstay of symptomatic therapy, but treatment with licensed doses relieves symptoms effectively in < 50% of patients. Although guideline-recommended updosing up to fourfold increases symptom control in many patients, a substantial number of patients have only little benefit from H -antihistamines. Consequently, there is a great need for new therapeutic strategies.
机译：慢性自发性荨麻疹（以前也称为慢性特发性荨麻疹和慢性荨麻疹）比以前认为的更为普遍。在任何时候，有0.5-1％的人口患有该疾病（点流行率）。尽管所有年龄段的人群都可能受到影响，但发病高峰出现在20至40岁之间。疾病的持续时间通常为1-5年，但在更严重的情况下，并发血管性水肿，物理性荨麻疹或自体血清皮肤试验阳性（自身反应性）的情况下，病程可能会更长。慢性自发性荨麻疹对生活质量有重大不利影响，睡眠不足和精神病合并症很常见。就直接和间接医疗保健费用以及工作和私人生活中的绩效下降而言，这也对社会产生了巨大影响。在大多数患者中，无法确定根本原因，因此很难进行因果和/或治愈性治疗。非镇静性H-抗组胺药是对症治疗的主体，但许可剂量的治疗可有效缓解50％以下的患者症状。尽管在许多患者中指南推荐的剂量增加至四倍可增加症状控制，但是相当多的患者对H-抗组胺药的益处很小。因此，非常需要新的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号